Editorial team
ioQuanta Research Desk
-
Evidence date ·Lightweight rocket tanks face a materials puzzle in deep cold and liquid oxygen
Review or Meta-AnalysisA 2021 review finds polymer strength and stiffness can rise in deep cold even as impact resistance falls, while liquid oxygen adds a chemical hazard.
-
Evidence date ·Why did a metal-binding composite slow algal growth?
Review or Meta-AnalysisA 2021 review explains how cellulose–polyethyleneimine composites bind metals, and how polymer release affected algae in one reported formulation.
-
Evidence date ·Could a persistent rash during immunotherapy matter before blisters?
Review or Meta-AnalysisA review of 58 cases found that an itchy eruption sometimes preceded blisters, and the skin disease often interrupted cancer immunotherapy.
-
Evidence date ·A lung biopsy can show which immune cells sit beside a tumor
Review or Meta-AnalysisA 2021 review shows how multiple stains reveal which cells carry PD-L1 and where immune cells sit in lung tumors. Earlier studies linked both patterns to survival.
-
Evidence date ·What recovered carbon fibers can become in new parts
Review or Meta-AnalysisA 2021 review estimated 24,000 tonnes of carbon-fiber waste but less than 1,000 tonnes recycled, citing uncertain material quality and buyer demand.
-
Evidence date ·Why a blood-cancer treatment faces different conditions inside solid tumors
Review or Meta-AnalysisCAR T cells can treat some B cell cancers. The review shows why solid tumors pose different hurdles: selecting a safe target, entering the tumor, and staying active inside it.
-
Evidence date ·Why did antibodies against an immune-cell brake fare differently in mice and people?
Review or Meta-AnalysisTracked over timeIn mice, anti-TIGIT antibodies that recruited other immune cells often controlled tumors better. In people, treatment alone disappointed and combinations gave mixed results.
-
Evidence date ·What the TIGIT immune brake reveals in myeloma and other blood cancers
Review or Meta-AnalysisTracked over timeMyeloma studies found that blocking TIGIT improved immune-cell activity in lab tests, while only some bone-marrow samples responded.
-
Evidence date ·What does CD155 do to tumor cells and immune cells, and where might TIGIT blockade fit?
Review or Meta-AnalysisTracked over timeA 2021 review reports that CD155 can promote cancer-cell growth. Its interaction with TIGIT can also inhibit immune cells, a reason to test TIGIT blockade.
-
Evidence date ·How microbes, additives and blends can change a brittle biodegradable plastic called PHB
Review or Meta-AnalysisMicrobes can build PHB copolymers, while additives and blends modify the material later. A 2021 review weighs gains and tradeoffs for packaging films.